BlackRock Institutional Trust’s Eledon Pharmaceuticals ELDN Stock Holding History

BlackRock Institutional Trust’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$132K	Hold	834	–	–	﹤0.01%	3625
2016 Q3	$207K	Buy	834 +69	+9%	+$25.2K	﹤0.01%	3606
2016 Q2	$682K	Sell	765 -46	-6%	-$50.7K	﹤0.01%	3428
2016 Q1	$737K	Sell	811 -16	-2%	-$15.7K	﹤0.01%	3369
2015 Q4	$1.17M	Buy	827 +64	+8%	+$112K	﹤0.01%	3288
2015 Q3	$1.28M	Buy	763 +380	+99%	+$783K	﹤0.01%	3260
2015 Q2	$825K	Buy	383 +93	+32%	+$180K	﹤0.01%	3407
2015 Q1	$532K	Buy	290 +23	+9%	+$50.7K	﹤0.01%	3490
2014 Q4	$637K	Buy	+267	New	+$634K	﹤0.01%	3455

Other funds holding ELDN

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock Institutional Trust's ELDN Position: Q4 2016 in Review

BlackRock Institutional Trust held its Eledon Pharmaceuticals (ELDN) position steady in Q4 2016 at 834 shares worth $132K. The position accounts for ﹤0.01% of the portfolio, ranked #3625.

BlackRock Institutional Trust first reported a position in ELDN in Q4 2014 and has held it in 9 quarters since. The position peaked at $1.28M in Q3 2015. 42 funds tracked by Wall St. Rank hold ELDN as of Q4 2016.

BlackRock Institutional Trust held 834 shares of Eledon Pharmaceuticals worth $132K as of Q4 2016.
BlackRock Institutional Trust left its Eledon Pharmaceuticals share count unchanged in Q4 2016.
Eledon Pharmaceuticals made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3625 holding.
BlackRock Institutional Trust first reported a position in Eledon Pharmaceuticals in Q4 2014 and has held it in 9 quarters since.
BlackRock Institutional Trust's Eledon Pharmaceuticals position peaked at $1.28M in Q3 2015.
42 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.